Opioids

Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth

08.11.20 | Sophie Shulman

The U.S. Opioid Abuse Lawsuits Are Political, Says Teva CEO

19.02.20 | Sophie Shulman

Teva Faces U.S. Criminal Probe on Opioid-Related Distribution, Report Says

27.11.19 | CTech

Teva Up 25% on NYSE Since Third Quarter Reports

17.11.19 | Sophie Shulman

Teva Overcomes One Hurdle, Many Still Ahead

23.10.19 | Hezi Sternlicht

Teva Consortium Fails to Reach Opioid Abuse Settlement, Report Says

20.10.19 | CTech

Teva Part of $50 Billion Opioid Settlement Deal, Report Says

17.10.19 | Hezi Sternlicht

Teva Part of Consortium Looking to Participate in Purdue Pharma's Bankruptcy, Report Says

02.10.19 | CTech

Allergan Says Teva Bears Sole Liability for Actavis' Actions

02.09.19 | Hezi Sternlicht

Teva Crashes Following Purdue Pharma $10-$12 Billion Settlement Reports

28.08.19 | Lilach Baumer

Teva Faces New Opioid-Related Lawsuit in West Virginia

25.08.19 | Hezi Sternlicht

Teva Jumps on NYSE on a Bit of Good News

21.08.19 | Hezi Sternlicht

Teva Falls on Pre-Market Trading After Morgan Stanley Downgrade

15.07.19 | CTech

Teva Reaches $85 Million Settlement in Oklahoma Opioid Damages Suit

27.05.19 | Hezi Sternlicht

Teva’s Shady Legal Past Still Weighs on the Debt-Laden Pharma Company

12.05.19 | Hezi Sternlicht